ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
31.64
+0.48 (+1.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close31.16
Open31.00
Bid31.66 x 800
Ask31.69 x 1400
Day's Range30.96 - 31.71
52 Week Range28.54 - 46.59
Volume123,598
Avg. Volume161,482
Market Cap449.658M
Beta (3Y Monthly)1.55
PE Ratio (TTM)24.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 days ago

    Anika to Issue First-Quarter 2019 Financial Results and Business Highlights on Thursday, May 2

    Anika Therapeutics, Inc. today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday, May 2, 2019, at 5:00 p.m.

  • Business Wire17 days ago

    Anika to Highlight Regenerative Medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting

    Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 2019 Asia Pacific Orthopaedic Association Sports Meeting.

  • Business Wirelast month

    Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development

    Industry veteran brings extensive experience leading high-performing R&D groups

  • Business Wirelast month

    Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting

    Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the upcoming American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, March 12-16 in Las Vegas, Nevada. Anika will be exhibiting its injectable, HA-based, surgical bone repair therapy in addition to its viscosupplement (CINGAL) and cartilage repair (HYALOFAST) solutions. “We’re excited to preview our bone repair therapy at the 2019 AAOS Annual Meeting, the largest gathering of orthopedic surgery professionals from around the world,” said Joseph Darling, President and CEO, Anika Therapeutics.

  • Business Wire2 months ago

    Anika Reports Fourth Quarter and Full Year 2018 Financial Results

    Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018

  • Business Wire2 months ago

    Anika to Issue Fourth-Quarter and Full-Year 2018 Financial Results and Business Highlights on Thursday, February 21

    Anika Therapeutics, Inc. today announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the same day, Thursday, February 21, 2019, at 5:00 p.m.

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for Cisco, Landstar System, Central Garden & Pet, Anika Therapeutics, Hibbett Sports, and MoneyGram International — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Anika Announces Plans to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Summit in San Diego

    Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, at the 2019 International Cartilage Repair Society Summit.

  • Business Wire4 months ago

    Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

    Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas Research University.

  • Business Wire5 months ago

    Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

    Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it has resumed global distribution of its solid HA-based treatments, including HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, after a voluntary, non-safety related recall in the second quarter of 2018. Following recent regulatory approvals in Thailand, the United Arab Emirates and Colombia, HYALOFAST has a commercial footprint in approximately 15 countries. “Since May, our quality and operations teams have worked tirelessly to get us back on line to resume shipments before the end of this year, and we’ve delivered on that promise,” said Joseph Darling, President and CEO, Anika Therapeutics.

  • GlobeNewswire6 months ago

    New Research: Key Drivers of Growth for Edison International, NuVasive, LogMein, Anika Therapeutics, First Industrial Realty Trust, and ON Semiconductor — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Anika Reports Third Quarter 2018 Financial Results

    CINGAL Drives Strong International Viscosupplement Revenue Growth

  • Business Wire6 months ago

    Susan Vogt Appointed to Board of Directors of Anika Therapeutics

    Anika Therapeutics, Inc. (ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt as an independent director. Ms. Vogt most recently served as Chief Executive Officer and Director of Aushon Biosystems, a venture-backed company with a novel multiplex immunoassay platform.

  • Business Wire6 months ago

    Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

    Anika Therapeutics, Inc. today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m.

  • Business Wire7 months ago

    Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

    Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that its President and Chief Executive Officer, Joseph Darling, and Chief Financial Officer, Sylvia Cheung, will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference on Wednesday, ...

  • Business Wire7 months ago

    Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

    Anika Therapeutics, Inc. (ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Keratin Biosciences, Inc., has been appointed as a new independent member of the Company’s Board of Directors with a term continuing through the Company’s 2019 Annual Meeting of Stockholders. With Dr. Blanchard’s appointment, the Board of Directors has been expanded to seven directors.

  • ACCESSWIRE9 months ago

    Blog Exposure - CHMP Adopts Positive Opinion for Alnylam’s Patisiran for HATTR Amyloidosis Treatment

    LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free research report on Alnylam Pharma, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company's latest news hit the wire. On July 27, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (EC), the medicine will be commercialized under the brand name ONPATTRO™.

  • Business Wire9 months ago

    Anika Reports Second Quarter 2018 Financial Results

    Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS

  • Business Wire9 months ago

    Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25

    Anika Therapeutics, Inc. today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July 26, 2018, at 9:00 a.m.

  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Anika Therapeutics and Tesaro

    NEW YORK, NY / ACCESSWIRE / June 21, 2018 / Shares of Anika Therapeutics were deep in the red on Wednesday after the company announced that its phase 3 study of CINGAL 16-02 failed to meet its primary end point. Shares of Tesaro were rising higher after a report surfaced that the company could be acquired by Roche Holdings. Anika Therapeutics, Inc. shares closed down 37.62% on about 3.5 million shares traded yesterday.

  • Business Wire10 months ago

    Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

    Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. CINGAL has previously been evaluated in a placebo-controlled Phase III clinical trial (13-01) that demonstrated safety and efficacy through 26-weeks. The 16-02 trial compared CINGAL, a combination of cross-linked HA and triamcinolone hexacetonide (TH), with TH alone and cross-linked HA in treating patients with osteoarthritis (OA) in the knee.

  • Business Wire11 months ago

    Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

    Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that it will enter into an accelerated share repurchase (ASR) program to repurchase $30 million of its outstanding common stock. “Our ASR program reflects Anika’s strong financial position and underscores our confidence in the outlook for the Company,” said Joseph Darling, President and CEO, Anika Therapeutics. The Company will enter into an accelerated stock repurchase agreement with Morgan Stanley & Co. LLC pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction to purchase $30 million of shares of its common stock.

  • Business Wire11 months ago

    Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress

    Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the 18th bi-annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress, being held in Glasgow, Scotland on May ...